Wegovy, a medication for chronic weight management, received FDA approval on June 4, 2021 [1]. It is indicated for adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) who have at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia [1].
What is Wegovy's active ingredient?
Wegovy's active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist [1]. Semaglutide mimics the action of the GLP-1 hormone, which helps regulate appetite and food intake [2].
How does Wegovy help with weight loss?
Semaglutide works by targeting appetite pathways in the brain. It can lead to reduced calorie intake by promoting feelings of fullness and satiety, thereby aiding in weight loss and maintenance [2].
What is the recommended Wegovy dosage?
The recommended maintenance dose of Wegovy is 2.4 mg administered once weekly by subcutaneous injection [1]. Treatment typically starts with a lower dose and is gradually increased over 16 weeks to reach the maintenance dose [1].
What clinical trials led to Wegovy's FDA approval?
Wegovy's approval was based on findings from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program [2]. The STEP 1 trial, a key study, demonstrated that participants treated with 2.4 mg of semaglutide weekly achieved an average weight loss of 14.9% over 68 weeks compared to a placebo [2].
What are the potential side effects of Wegovy?
Common side effects of Wegovy include nausea, vomiting, diarrhea, abdominal pain, and constipation [1]. These gastrointestinal side effects are often dose-dependent and can decrease over time as the body adjusts to the medication [2]. More serious, though less common, risks include pancreatitis, gallbladder disease, and kidney problems [1]. Wegovy also carries a boxed warning for thyroid C-cell tumors, based on animal studies [1].
When does Wegovy's patent expire?
Information regarding specific patent expiry dates for Wegovy is available through resources like DrugPatentWatch.com. These patents are crucial for determining when generic versions of the drug might become available [3].
Who manufactures Wegovy?
Wegovy is manufactured by Novo Nordisk [1].
How does Wegovy compare to other weight loss medications?
Wegovy belongs to the GLP-1 receptor agonist class, similar to liraglutide (Saxenda) and semaglutide's use in type 2 diabetes (Ozempic). While Saxenda also promotes weight loss, Wegovy has demonstrated a higher percentage of weight loss in clinical trials [2]. Other classes of weight loss medications work through different mechanisms, such as appetite suppressants or fat absorption inhibitors.
---
Sources
[1] https://www.drugs.com/wegovy.html
[2] https://www.novomedlink.com/obesity/wegovy/about-wegovy.html
[3] https://drugpatentwatch.com/